A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway
| Autor: | Luyao, Wang, Wenliya, Dong, Huan, Gao, Chuchu, Chen, Siyu, Liang, Xianxi, Ye, Yi, Liu, Yushu, Hou, Lei, Fan, Tongtong, Pan, Zengshou, Wang, Yongping, Chen, Yongde, Luo, Lintao, Song |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Inflammation
Liver Cirrhosis Carcinoma Hepatocellular Tumor Necrosis Factor-alpha Drinking Water Fatty Acids Liver Neoplasms Fibroblast Growth Factor 4 Palmitic Acid Fructose AMP-Activated Protein Kinases Mice Inbred C57BL Mice Glucose Cyclohexanes Non-alcoholic Fatty Liver Disease Animals Molecular Medicine Molecular Biology |
| Zdroj: | Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1868:166560 |
| ISSN: | 0925-4439 |
| DOI: | 10.1016/j.bbadis.2022.166560 |
| Popis: | Non-alcoholic fatty liver disease (NAFLD) has emerged as a major liver disease increasingly in association with non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). However, there are currently no approved therapies for treating NAFLD and NASH. Fibroblast growth factor 4 (FGF4) has recently been shown as a promising drug candidate for several metabolic diseases.Mice fed a high-fat diet with high fructose/glucose drinking water (HF/HFG, Western-like diet) for 21 weeks were intraperitoneally injected with non-mitogenic recombinant FGF4Administration of rFGF4rFGF4 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect